Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

The company targets oncologists, healthcare providers, and biopharmaceutical partners focused on innovative cancer treatments for solid tumor patients.Bicara Therapeutics develops bifunctional antibody-based therapies for solid tumors, with its lead product candidate being ficerafusp alfa targeting EGFR and TGF-beta pathways.* 1-year performance is calculated using March 6, 2026 as the reference date.How does this event fit within the historical pattern of insider activity? Across seven reported transaction ...